Articles Deaths potentially averted by small changes in physical activity and sedentary time: an individual participant data meta-analysis of prospective cohort studies Ulf Ekelund, Jakob Tarp, Ding Ding, et al Lancet 2026; 407: 339-349 https://doi.org/10.1016/S0140-6736(25)02219-6 Summary Background The effects of small, realistic changes in physical activity and sedentary behaviour on population-level mortality are unclear. We aimed to estimate the ...

Landmark Study: Sepsis Risk and Long-Term Outcomes In Sepsis Tue, 17 Mar 2026 A landmark population-based study on the developmental risk factors and long-term consequences of sepsis was previewed at ISICEM this afternoon. Djillali Annane, director of the ICU and the IHU-PROMETHEUS Comprehensive Sepsis Center at Raymond Poincaré Hospital in Paris, presented early insights from the ongoing research in a French cohort. Drawing on more than 25 years of...

PERIOPERATIVE MEDICINE Individualized Flow-controlled versus Pressure-controlled Ventilation in Cardiac Surgery: A Randomized Controlled Trial Becker, Simon; Kurz, Christian T; Schnitzler, Romina, et al Anesthesiology January 14, 2026. | DOI: 10.1097/ALN.0000000000005851 Background:  Patients undergoing on-pump cardiac surgery are at high risk for perioperative lung injury and a hyperinflammatory state associated with postoperative complications. The a...

Round Table @ISICEM: Rethinking ICU Myths and Misconceptions In ICU Wed, 18 Mar 2026 An interesting Round Table session @ISICEM, Rethinking ICU myths and misconceptions, challenged clinicians to reconsider how much of intensive care practice is truly evidence-based versus driven by entrenched beliefs. The expert meeting aimed not simply to criticise current practices, but to understand how and why certain clinical beliefs become embedded, even ...

High-Flow or Standard Oxygen in Acute Hypoxaemic Respiratory Failure In ICU Tue, 17 Mar 2026 Findings from the SOHO (Standard Oxygen versus High-Flow Oxygen Therapy in Acute Hypoxemic Respiratory Failure) trial were presented @ISICEM this morning. The SOHO trial compared high-flow nasal oxygen with standard oxygen therapy in adults with acute hypoxaemic respiratory failure. The study addresses an important clinical question: oxygen therapy is the fi...

ARTICLES Online firstMarch 16, 2026 Epidemiology, ventilation, and outcomes of acute respiratory failure in immunocompromised patients from 103 intensive care units in 26 countries: a retrospective observational study Elie Azoulay, Colleen McEvoy, Pedro Castro, et al Lancet Respir Med Published March 16, 2026 DOI: 10.1016/S2213-2600(26)00046-9  Summary Background Acute hypoxaemic respiratory failure (ARF) is the leading cause of intensive care unit (I...

EDITORIAL The COBRRA Trial — Ending the Venous Thromboembolism Safety Toss-up Lisa K. Moores N Engl J Med 2026;394:1123-1124 DOI: 10.1056/NEJMe2600525 The landscape of treatment options for venous thromboembolism was transformed by the arrival of direct oral anticoagulants. Large-scale trials showed that the direct oral anticoagulants apixaban and rivaroxaban were noninferior to vitamin K antagonists in terms of efficacy and had a better safety profile. How...

ORIGINAL ARTICLE High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure Jean-Pierre Frat, Jean-Pierre Quenot, Christophe Guitton, et al N Engl J Med Published March 17, 2026 Abstract BACKGROUND Data are needed on the effect of oxygen delivered through a high-flow nasal cannula, as compared with standard oxygen therapy, on intubation and mortality in patients with acute hypoxemic respiratory failure. METHODS In this multicenter, open-la...

Editorial  Physical Restraint Use in Critical Care: Balancing Safety and Harm Kimberley J. Haines, Maj-Brit Nørregaard Kjær, Adam M. Deane JAMA Published Online: March 17, 2026 doi: 10.1001/jama.2026.2785 I was already fighting so much, not only for my life, but just like the need for a drop of water and any basic human need was being taken away anyway and then not to have the use of your bodily parts, your hands to hug somebody, to wipe away tears, t...

ORIGINAL ARTICLE Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, et al N Engl J Med 2026;394:1051-1060 DOI: 10.1056/NEJMoa2510703 Abstract BACKGROUND Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two medications. METHODS ...